MUSC background

MUSC Recognized for CLABSI Reduction

In May 2013, Cassandra D. Salgado, M.D., MS, hospital epidemiologist at MUSC, and Linda Formby, RN, CIC, Manager for Infection Prevention and Control, traveled to Boston to receive the “Outstanding Achievement and Leadership Award for Elimination of Central Line –Associated Bloodstream Infections (CLABSI)” from the Department of Health and Human Services and the Critical Care Societies Collaborative. In this year’s group of hospitals and health care organizations recognized for achieving excellence in reducing hospital-acquired infections, MUSC was the only institution tapped for reducing CLABSI by more than 50% in four critical care areas throughout a 36-month period: the neurosurgical intensive care unit (ICU; 71%), cardiothoracic ICU (73%), pediatric ICU (95%), and pediatric cardiothoracic ICU (91%). Dr. Salgado estimates that these reductions prevented 369 CLABSI, saving 66 patient lives and $13.3 million in health care costs. MUSC was also recognized for its facility-wide reduction of CLABSI.

Since 2005, MUSC’s CLABSI rates have dropped by 80%. This success can be attributed to the adoption of an insertion bundle in 2007 and a maintenance bundle in 2008, the institution in 2008 of a ZERO BSI initiative by Dr. Salgado and Ms. Formby, and the integration of the Comprehensive Unit-based Safety Program (CUSP) model in 2009 into the hospital’s efforts. Also key was the steadfast support of the senior administration, who integrated CLABSI reduction into the strategic aims of the hospital, making it an institution-wide effort.

In the words of Dr. Salgado, “This recognition reflects continued dedication and collaboration between all care providers in the ICU, infection preventionists, and support from hospital leadership to change the culture of safety. This should serve as a model for future prevention efforts.” (Adapted from an article by Cindy Abole in MUSC’s Catalyst).

PERCENT REDUCTION IN INFECTION RATES SINCE 2009

VAP                                         37%

MRSA/VRE acquisition     41%
   

VAP - Ventilator-acquired pneumonia; MRSA - Methicillin-resistant Staphylococcus aureus; VRE - Vancomycin-resistant enterococci